Monopar Therapeutics (NASDAQ:MNPR) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a sell rating to a hold rating in a research report report published on Saturday.

Other research analysts have also issued reports about the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, July 15th. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. HC Wainwright boosted their price target on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a research report on Wednesday, July 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, Piper Sandler set a $105.00 price objective on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $112.08.

Monopar Therapeutics Trading Down 0.8%

Shares of NASDAQ:MNPR opened at $119.21 on Friday. The firm’s 50 day moving average is $90.83 and its two-hundred day moving average is $70.05. The firm has a market capitalization of $798.59 million, a P/E ratio of -62.74 and a beta of 1.47. Monopar Therapeutics has a 52 week low of $29.18 and a 52 week high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. Analysts predict that Monopar Therapeutics will post -2.82 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics in the 3rd quarter valued at approximately $28,000. BNP Paribas Financial Markets grew its holdings in shares of Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after acquiring an additional 349 shares in the last quarter. Sei Investments Co. increased its stake in shares of Monopar Therapeutics by 9.5% in the first quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock worth $415,000 after acquiring an additional 656 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Monopar Therapeutics in the fourth quarter worth $65,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in shares of Monopar Therapeutics during the fourth quarter worth $86,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.